You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluoxetine
Accession NumberDB00472  (APRD00530)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionFluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Fluoxetine may be used to treat major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and in combination with olanzapine for treatment-resistant or bipolar I depression. Fluoxetine is the most anorexic and stimulating SSRI.
Structure
Thumb
Synonyms
(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine
(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
Fluoxetin
Fluoxetina
Fluoxétine
Fluoxetinum
Prozac
External Identifiers
  • Lilly 103472
  • Lilly 110 140
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-fluoxetineCapsule10 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-fluoxetineCapsule20 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Ach-fluoxetineCapsule10 mgOralAccord Healthcare Inc2012-10-10Not applicableCanada
Ach-fluoxetineCapsule20 mgOralAccord Healthcare Inc2012-05-01Not applicableCanada
Act FluoxetineCapsule10 mgOralDr Reddys Laboratories Inc2000-05-31Not applicableCanada
Act FluoxetineCapsule40 mgOralDr Reddys Laboratories IncNot applicableNot applicableCanada
Act FluoxetineCapsule20 mgOralDr Reddys Laboratories Inc2000-05-31Not applicableCanada
Auro-fluoxetineCapsule20 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-fluoxetineCapsule10 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Ava-fluoxetineCapsule20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Bci FluoxetineCapsule20 mgOralBaker Cummins IncNot applicableNot applicableCanada
Bio-fluoxetineCapsule10 mgOralBiomed Pharma2016-10-25Not applicableCanada
Bio-fluoxetineCapsule20 mgOralBiomed Pharma2016-10-25Not applicableCanada
Dom-fluoxetineCapsule20 mgOralDominion Pharmacal1995-12-31Not applicableCanada
Dom-fluoxetine - Cap 10mgCapsule10 mgOralDominion Pharmacal1995-12-31Not applicableCanada
FluoxetineCapsule20 mgOralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
FluoxetineCapsule10 mgOralMeliapharm Inc2010-06-112014-06-25Canada
FluoxetineCapsule20 mgOralSanis Health Inc2009-10-22Not applicableCanada
FluoxetineCapsule20 mgOralMeliapharm Inc2010-06-112014-06-25Canada
FluoxetineSolution20 mgOralAa Pharma Inc1997-06-16Not applicableCanada
FluoxetineCapsule10 mgOralSivem Pharmaceuticals Ulc2011-10-14Not applicableCanada
FluoxetineCapsule10 mgOralSanis Health Inc2009-10-22Not applicableCanada
Fluoxetine CapsulesCapsule10 mgOralPharmascience Inc1999-11-10Not applicableCanada
Fluoxetine CapsulesCapsule20 mgOralPharmascience Inc1999-11-10Not applicableCanada
Fluoxetine HClTablet, film coated60 mg/1OralEdgemont Pharmaceuticals, Llc2011-11-14Not applicableUs
Fluoxetine-10 - CapCapsule10 mgOralPro Doc Limitee1997-04-302010-07-13Canada
Fluoxetine-20 - CapCapsule20 mgOralPro Doc Limitee1997-04-302010-07-13Canada
Fxt 10Capsule10 mgOralOryx Pharmaceuticals Inc A Subsidiary Of Filiale D'arrow Pharmaceuticals Inc2002-11-012004-08-04Canada
Fxt 20Capsule20 mgOralOryx Pharmaceuticals Inc A Subsidiary Of Filiale D'arrow Pharmaceuticals Inc2002-11-012004-08-04Canada
Fxt 40Capsule40 mgOralSepracor Pharmaceuticals Inc2002-06-212011-08-03Canada
Ipg-fluoxetineCapsule20 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-fluoxetineCapsule10 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Jamp-fluoxetineCapsule10 mgOralJamp Pharma Corporation2013-04-30Not applicableCanada
Jamp-fluoxetineCapsule20 mgOralJamp Pharma Corporation2012-06-07Not applicableCanada
Mar-fluoxetineCapsule10 mgOralMarcan Pharmaceuticals Inc2013-05-07Not applicableCanada
Mar-fluoxetineCapsule20 mgOralMarcan Pharmaceuticals Inc2013-06-27Not applicableCanada
Mint-fluoxetineCapsule10 mgOralMint Pharmaceuticals Inc2012-03-20Not applicableCanada
Mint-fluoxetineCapsule20 mgOralMint Pharmaceuticals Inc2012-03-20Not applicableCanada
Mylan-fluoxetineCapsule20 mgOralMylan Pharmaceuticals Ulc1998-04-23Not applicableCanada
Mylan-fluoxetineCapsule10 mgOralMylan Pharmaceuticals Ulc1998-04-23Not applicableCanada
Nu-fluoxetineCapsule20 mgOralNu Pharm Inc1996-12-312012-09-04Canada
Nu-fluoxetineLiquid20 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-fluoxetineCapsule10 mgOralNu Pharm Inc1996-12-312012-09-04Canada
Penta-fluoxetine CapsulesCapsule10 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-fluoxetine CapsulesCapsule20 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PHL-fluoxetine - Cap 10mgCapsule10 mgOralPharmel Inc1998-06-04Not applicableCanada
PHL-fluoxetine - Cap 20mgCapsule20 mgOralPharmel Inc1998-06-04Not applicableCanada
PHL-fluoxetine - Solution 20mg/5mlSolution20 mgOralPharmel Inc1998-06-04Not applicableCanada
PMS-fluox Capsules 20mgCapsule20 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-fluoxetine - Cap 10mgCapsule10 mgOralPharmascience Inc1995-12-31Not applicableCanada
PMS-fluoxetine - Cap 20mgCapsule20 mgOralPharmascience Inc1995-12-31Not applicableCanada
PMS-fluoxetine Liquid - 20mg/5mlSolution20 mgOralPharmascience Inc1997-10-20Not applicableCanada
Priva-fluoxetineCapsule10 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-fluoxetineCapsule20 mgOralPharmapar IncNot applicableNot applicableCanada
Pro-fluoxetineCapsule10 mgOralPro Doc Limitee2008-10-15Not applicableCanada
Pro-fluoxetineCapsule20 mgOralPro Doc Limitee2008-10-15Not applicableCanada
ProzacCapsule10 mg/1OralDista Products Company1993-01-13Not applicableUs
ProzacCapsule20 mg/1OralStat Rx USA1987-12-29Not applicableUs
ProzacCapsule20 mg/1OralDista Products Company1988-02-01Not applicableUs
ProzacCapsule40 mg/1OralDista Products Company1999-06-15Not applicableUs
Prozac Capsules 10mgCapsule10 mgOralEli Lilly Canada Inc1993-12-31Not applicableCanada
Prozac Capsules 20mgCapsule20 mgOralEli Lilly Canada Inc1989-12-31Not applicableCanada
Prozac Liq 20mg/5mlLiquid20 mgOralEli Lilly Canada Inc1992-12-312007-08-29Canada
Prozac WeeklyCapsule, delayed release90 mg/1OralEli Lilly and Company2001-03-16Not applicableUs
Q-fluoxetineCapsule20 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-fluoxetineCapsule10 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-fluoxetineCapsule10 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-07-08Not applicableCanada
Ran-fluoxetineCapsule20 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-07-08Not applicableCanada
Ratio-fluoxetineCapsule20 mgOralRatiopharm Inc Division Of Teva Canada Limited2000-01-242014-09-19Canada
Ratio-fluoxetineCapsule10 mgOralRatiopharm Inc Division Of Teva Canada Limited2000-01-242014-09-19Canada
Riva-fluoxetineCapsule20 mgOralLaboratoire Riva Inc2009-09-21Not applicableCanada
Riva-fluoxetineCapsule10 mgOralLaboratoire Riva Inc2000-05-232014-07-29Canada
Riva-fluoxetineCapsule10 mgOralLaboratoire Riva Inc2010-10-22Not applicableCanada
Riva-fluoxetineCapsule20 mgOralLaboratoire Riva Inc2000-05-232013-07-31Canada
Sandoz FluoxetineCapsule10 mgOralSandoz Canada Incorporated2001-02-22Not applicableCanada
Sandoz FluoxetineCapsule20 mgOralSandoz Canada Incorporated2001-02-22Not applicableCanada
SarafemTablet10 mg/1OralAllergan, Inc.2008-06-24Not applicableUs
SarafemTablet20 mg/1OralAllergan, Inc.2008-06-24Not applicableUs
Stcc-fluoxetine - Cap 10mgCapsule10 mgOralStcc Inc.1995-12-312002-07-31Canada
Stcc-fluoxetine - Cap 20mgCapsule20 mgOralStcc Inc.1995-12-312002-07-31Canada
Teva-fluoxetineCapsule20 mgOralTeva Canada Limited1996-12-31Not applicableCanada
Teva-fluoxetineCapsule10 mgOralTeva Canada Limited1996-12-31Not applicableCanada
Van-fluoxetineCapsule10 mgOralVanc Pharmaceuticals Inc2015-07-07Not applicableCanada
Van-fluoxetineCapsule20 mgOralVanc Pharmaceuticals Inc2015-07-07Not applicableCanada
Zym-fluoxetineCapsule20 mgOralZymcan Pharmaceuticals Inc2009-02-262014-06-16Canada
Zym-fluoxetineCapsule10 mgOralZymcan Pharmaceuticals Inc2009-02-262014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fluoxetineCapsule20 mgOralApotex Inc1996-12-31Not applicableCanada
Apo-fluoxetineCapsule10 mgOralApotex Inc1996-12-31Not applicableCanada
FluoxetineSolution20 mg/5mLOralMorton Grove Pharmaceuticals, Inc.2002-08-29Not applicableUs
FluoxetineCapsule40 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-11-18Not applicableUs
FluoxetineCapsule20 mg/1OralLife Line Home Care Services, Inc.2012-01-16Not applicableUs
FluoxetineCapsule10 mg/1OralRebel Distributors Corp2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralRebel Distributors Corp2002-01-29Not applicableUs
FluoxetineCapsule10 mg/1OralPreferred Pharmaceuticals, Inc.2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralClinical Solutions Wholesale, Llc2002-01-29Not applicableUs
FluoxetineCapsule40 mg/1OralPar Pharmaceutical Companies, Inc.2008-12-08Not applicableUs
FluoxetineCapsule20 mg/1OralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
FluoxetineCapsule10 mg/1OralMed Health Pharma, LLC2011-01-15Not applicableUs
FluoxetineCapsule20 mg/1OralDIRECT RX2016-10-25Not applicableUs
FluoxetineCapsule40 mg/1OralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
FluoxetineCapsule40 mg/1OralTeva Pharmaceuticals USA Inc2012-08-29Not applicableUs
FluoxetineCapsule20 mg/1OralREMEDYREPACK INC.2013-06-032016-04-05Us
FluoxetineCapsule10 mg/1OralCardinal Health2002-01-29Not applicableUs
FluoxetineTablet, film coated10 mg/1OralProficient Rx LP2002-01-30Not applicableUs
FluoxetineCapsule20 mg/1OralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
FluoxetineCapsule20 mg/1OralREMEDYREPACK INC.2013-03-182016-11-01Us
FluoxetineCapsule10 mg/1OralCardinal Health2007-02-16Not applicableUs
FluoxetineCapsule20 mg/1OralA S Medication Solutions2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralMedsource Pharmaceuticals2009-06-09Not applicableUs
FluoxetineCapsule20 mg/1OralMed Vantx, Inc.2012-03-20Not applicableUs
FluoxetineCapsule20 mg/1OralProdigy Health Supplier2012-06-01Not applicableUs
FluoxetineCapsule10 mg/1OralNorth Star Rx Llc2009-07-01Not applicableUs
FluoxetineCapsule40 mg/1OralPd Rx Pharmaceuticals, Inc.2008-12-08Not applicableUs
FluoxetineCapsule20 mg/1OralPd Rx Pharmaceuticals, Inc.2008-01-31Not applicableUs
FluoxetineSolution20 mg/5mLOralTeva Pharmaceuticals Usa, Inc.2001-08-02Not applicableUs
FluoxetineCapsule10 mg/1OralPliva Inc.2002-01-29Not applicableUs
FluoxetineCapsule10 mg/1OralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
FluoxetineCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.2002-10-15Not applicableUs
FluoxetineCapsule20 mg/1Oralbryant ranch prepack2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralAmerican Health Packaging2013-02-04Not applicableUs
FluoxetineCapsule40 mg/1OralTeva Pharmaceuticals Usa, Inc.2002-01-30Not applicableUs
FluoxetineCapsule40 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
FluoxetineCapsule40 mg/1OralAurobindo Pharma Limited2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralA S Medication Solutions2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
FluoxetineCapsule20 mg/1OralUnit Dose Services2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralBarr Laboratories Inc.2001-08-02Not applicableUs
FluoxetineTablet, film coated20 mg/1OralREMEDYREPACK INC.2016-08-31Not applicableUs
FluoxetineCapsule20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-08-19Not applicableUs
FluoxetineCapsule40 mg/1OralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
FluoxetineCapsule20 mg/1OralMed Health Pharma, LLC2011-01-15Not applicableUs
FluoxetineCapsule10 mg/1OralCarlsbad Technology, Inc.2002-01-30Not applicableUs
FluoxetineCapsule20 mg/1OralReady Meds2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralMc Kesson Contract Packaging2011-10-17Not applicableUs
FluoxetineCapsule20 mg/1OralRebel Distributors Corp2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralPreferred Pharmaceuticals, Inc.2008-01-31Not applicableUs
FluoxetineCapsule40 mg/1OralClinical Solutions Wholesale2005-07-20Not applicableUs
FluoxetineCapsule20 mg/1OralA S Medication Solutions2008-01-31Not applicableUs
FluoxetineCapsule40 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-02Not applicableUs
FluoxetineCapsule10 mg/1OralAv Pak2014-08-20Not applicableUs
FluoxetineSolution20 mg/5mLOralPharmaceutical Associates, Inc.2002-01-30Not applicableUs
FluoxetineCapsule20 mg/1OralCardinal Health2011-07-11Not applicableUs
FluoxetineCapsule10 mg/1OralProficient Rx LP2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralContract Pharmacy Services Pa2011-01-25Not applicableUs
FluoxetineCapsule40 mg/1OralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
FluoxetineCapsule10 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
FluoxetineCapsule20 mg/1OralAidarex Pharmaceuticals LLC2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
FluoxetineCapsule20 mg/1OralProficient Rx LP2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralMed Vantx, Inc.2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralNorth Star Rx Llc2009-07-01Not applicableUs
FluoxetineCapsule10 mg/1OralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
FluoxetineCapsule20 mg/1OralDIRECT RX2014-01-01Not applicableUs
FluoxetineCapsule20 mg/1OralPliva Inc.2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralREMEDYREPACK INC.2013-02-252016-04-05Us
FluoxetineCapsule10 mg/1OralClinical Solutions Wholesale2002-01-29Not applicableUs
FluoxetineCapsule40 mg/1Oralbryant ranch prepack2008-12-08Not applicableUs
FluoxetineCapsule20 mg/1OralLegacy Pharmaceutical Packaging2011-01-25Not applicableUs
FluoxetineTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2013-12-23Not applicableUs
FluoxetineCapsule10 mg/1OralSTAT Rx USA LLC2012-03-20Not applicableUs
FluoxetineCapsule20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2008-01-31Not applicableUs
FluoxetineSolution20 mg/5mLOralAurobindo Pharma Limited2009-03-19Not applicableUs
FluoxetineTablet, film coated10 mg/1OralDr.Reddy's Laboratories Limited2016-09-30Not applicableUs
FluoxetineCapsule40 mg/1OralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
FluoxetineCapsule40 mg/1OralUnit Dose Services2005-07-20Not applicableUs
FluoxetineCapsule20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-29Not applicableUs
FluoxetineCapsule20 mg/1OralREMEDYREPACK INC.2016-02-25Not applicableUs
FluoxetineCapsule40 mg/1OralProficient Rx LP2015-03-16Not applicableUs
FluoxetineCapsule10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-05-24Not applicableUs
FluoxetineTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2002-01-30Not applicableUs
FluoxetineCapsule40 mg/1OralMed Health Pharma, LLC2011-01-15Not applicableUs
FluoxetineCapsule20 mg/1OralCarlsbad Technology, Inc.2002-01-30Not applicableUs
FluoxetineCapsule10 mg/1OralTYA Pharmaceuticals2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralMc Kesson Contract Packaging2012-04-16Not applicableUs
FluoxetineCapsule20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-01-29Not applicableUs
FluoxetineCapsule40 mg/1OralRebel Distributors Corp2005-07-20Not applicableUs
FluoxetineCapsule10 mg/1OralAidarex Pharmaceuticals LLC2002-01-29Not applicableUs
FluoxetineCapsule10 mg/1OralAurobindo Pharma Limited2008-01-31Not applicableUs
FluoxetineCapsule10 mg/1OralA S Medication Solutions2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-03Not applicableUs
FluoxetineCapsule20 mg/1OralAv Pak2014-08-20Not applicableUs
FluoxetineSolution20 mg/5mLOralPharmaceutical Associates, Inc.2002-02-01Not applicableUs
FluoxetineCapsule10 mg/1OralState of Florida DOH Central Pharmacy2012-06-01Not applicableUs
FluoxetineCapsule20 mg/1OralCardinal Health2013-02-04Not applicableUs
FluoxetineCapsule40 mg/1OralRanbaxy Pharmaceuticals Inc.2005-07-20Not applicableUs
FluoxetineCapsule10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralBlenheim Pharmacal, Inc.2009-12-22Not applicableUs
FluoxetineCapsule40 mg/1OralDr.Reddy's Laboratories Limited2002-10-15Not applicableUs
FluoxetineCapsule10 mg/1OralProficient Rx LP2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralMed Vantx, Inc.2002-01-29Not applicableUs
FluoxetineCapsule40 mg/1OralNorth Star Rx Llc2009-07-01Not applicableUs
FluoxetineCapsule20 mg/1OralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
FluoxetineCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.2008-01-31Not applicableUs
FluoxetineTablet10 mg/1OralTorrent Pharmaceuticals Limited2016-10-21Not applicableUs
FluoxetineCapsule10 mg/1OralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
FluoxetineCapsule10 mg/1OralREMEDYREPACK INC.2013-02-262016-04-05Us
FluoxetineCapsule10 mg/1OralMajor Pharmaceuticals2007-02-16Not applicableUs
FluoxetineCapsule10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-05-20Not applicableUs
FluoxetineLiquid20 mg/5mLOralSilarx Pharmaceuticals, Inc2009-08-27Not applicableUs
FluoxetineCapsule20 mg/1OralClinical Solutions Wholesale2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-11-18Not applicableUs
FluoxetineCapsule10 mg/1OralLegacy Pharmaceutical Packaging2011-01-31Not applicableUs
FluoxetineTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2013-12-23Not applicableUs
FluoxetineCapsule20 mg/1OralSTAT Rx USA LLC2010-04-29Not applicableUs
FluoxetineCapsule40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2005-07-20Not applicableUs
FluoxetineCapsule40 mg/1OralBlue Point Laboratories2013-12-23Not applicableUs
FluoxetineCapsule10 mg/1OralClinical Solutions Wholesale, Llc2002-01-29Not applicableUs
FluoxetineCapsule10 mg/1OralCamber Pharmaceuticals, Inc.2015-07-30Not applicableUs
FluoxetineCapsule10 mg/1OralUnit Dose Services2008-01-31Not applicableUs
FluoxetineCapsule10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralSTAT Rx USA LLC2012-03-20Not applicableUs
FluoxetineCapsule40 mg/1OralAv Kare, Inc.2016-09-06Not applicableUs
FluoxetineCapsule40 mg/1OralAvera Mc Kennan Hospital2015-03-05Not applicableUs
FluoxetineCapsule40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
FluoxetineCapsule20 mg/1OralREMEDYREPACK INC.2016-12-01Not applicableUs
FluoxetineCapsule10 mg/1OralPhysicians Total Care, Inc.2007-11-28Not applicableUs
FluoxetineCapsule20 mg/1OralTYA Pharmaceuticals2008-01-31Not applicableUs
FluoxetineCapsule10 mg/1OralProdigy Health Supplier2012-06-01Not applicableUs
FluoxetineCapsule40 mg/1OralAmerican Health Packaging2013-12-10Not applicableUs
FluoxetineTablet, film coated10 mg/1OralTeva Pharmaceuticals Usa, Inc.2002-01-30Not applicableUs
FluoxetineCapsule10 mg/1OralBlenheim Pharmacal, Inc.2009-12-22Not applicableUs
FluoxetineCapsule40 mg/1OralAidarex Pharmaceuticals LLC2005-07-20Not applicableUs
FluoxetineCapsule20 mg/1OralAurobindo Pharma Limited2008-01-31Not applicableUs
FluoxetineCapsule40 mg/1OralA S Medication Solutions2008-12-08Not applicableUs
FluoxetineCapsule20 mg/1OralREMEDYREPACK INC.2014-11-06Not applicableUs
FluoxetineCapsule10 mg/1OralVensun Pharmaceuticals, Inc.2015-03-16Not applicableUs
FluoxetineCapsule40 mg/1OralAv Pak2014-08-20Not applicableUs
FluoxetineCapsule10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
FluoxetineCapsule20 mg/1OralPd Rx Pharmaceuticals, Inc.2002-01-29Not applicableUs
FluoxetineCapsule10 mg/1Oralbryant ranch prepack2008-01-31Not applicableUs
FluoxetineCapsule20 mg/1OralMajor Pharmaceuticals2007-02-16Not applicableUs
FluoxetineCapsule40 mg/1OralProficient Rx LP2005-07-20Not applicableUs
FluoxetineCapsule10 mg/1OralContract Pharmacy Services Pa2010-07-30Not applicableUs
FluoxetineCapsule10 mg/1OralAlembic Pharmaceuticals Inc.2016-01-29Not applicableUs
FluoxetineCapsule20 mg/1OralCardinal Health2007-02-16Not applicableUs
FluoxetineCapsule40 mg/1OralHeritage Pharmaceuticals Inc.2012-06-29Not applicableUs
FluoxetineTablet20 mg/1OralTorrent Pharmaceuticals Limited2016-10-21Not applicableUs
FluoxetineCapsule20 mg/1OralScie Gen Pharmaceuticals, Inc.2015-03-16Not applicableUs
FluoxetineCapsule10 mg/1OralREMEDYREPACK INC.2013-05-09Not applicableUs
Fluoxetine HClCapsule40 mg/1OralDIRECT RX2015-01-01Not applicableUs
Fluoxetine HydrochlorideCapsule40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-01-29Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralPhysicians Total Care, Inc.2008-10-23Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralMylan Pharmaceuticals Inc.2008-11-17Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralContract Pharmacy Services Pa2010-04-05Not applicableUs
Fluoxetine HydrochlorideTablet, film coated20 mg/1OralRebel Distributors Corp2010-01-13Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralNorthwind Pharmaceuticals, LLC2014-11-03Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralSandoz Inc2001-08-02Not applicableUs
Fluoxetine HydrochlorideTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-01-13Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralREMEDYREPACK INC.2011-09-20Not applicableUs
Fluoxetine HydrochlorideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine HydrochlorideTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-13Not applicableUs
Fluoxetine HydrochlorideTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2003-08-19Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralMylan Pharmaceuticals Inc.2008-11-17Not applicableUs
Fluoxetine HydrochlorideTablet, film coated10 mg/1OralAv Kare, Inc.2012-08-30Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralREMEDYREPACK INC.2011-07-21Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.2001-08-02Not applicableUs
Fluoxetine HydrochlorideTablet, coated10 mg/1OralPar Pharmaceutical Inc.2016-08-22Not applicableUs
Fluoxetine HydrochlorideCapsule40 mg/1OralSandoz Inc2002-01-29Not applicableUs
Fluoxetine HydrochlorideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluoxetine HydrochlorideTablet, film coated10 mg/1OralPar Pharmaceutical, Inc2001-08-022016-11-30Us
Fluoxetine HydrochlorideTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-13Not applicableUs
Fluoxetine HydrochlorideCapsule40 mg/1OralPhysicians Total Care, Inc.2008-07-25Not applicableUs
Fluoxetine HydrochlorideTablet, film coated20 mg/1OralAv Kare, Inc.2012-08-30Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralREMEDYREPACK INC.2010-12-21Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-01-29Not applicableUs
Fluoxetine HydrochlorideTablet, coated20 mg/1OralPar Pharmaceutical Inc.2016-08-22Not applicableUs
Fluoxetine HydrochlorideTablet, film coated20 mg/1OralPar Pharmaceutical, Inc2001-08-02Not applicableUs
Fluoxetine HydrochlorideTablet, film coated10 mg/1OralRebel Distributors Corp2010-01-13Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralNorthwind Pharmaceuticals2014-05-20Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralSandoz Inc2002-01-29Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralKAISER FOUNDATION HOSPITALS2010-04-14Not applicableUs
Fluoxetine HydrochlorideCapsule, delayed release pellets90 mg/1OralDr.Reddy's Laboratories Limited2010-03-24Not applicableUs
Fluoxetine HydrochlorideCapsule10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2001-08-02Not applicableUs
Fluoxetine HydrochlorideCapsule20 mg/1OralA S Medication Solutions2002-01-29Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdofenBrainpharma
Animex-OnLaboratorios
FluoxerenMenarini
FontexLilly
LadoseLilly
Brand mixtures
NameLabellerIngredients
GaboxetinePhysician Therapeutics Llc
Olanzapine and FluoxetineSandoz Inc
Sentraflox Am-10Physician Therapeutics Llc
SentroxatinePhysician Therapeutics Llc
SymbyaxEli Lilly and Company
Salts
Name/CASStructureProperties
Fluoxetine Hydrochloride
56296-78-7
Thumb
  • InChI Key: GIYXAJPCNFJEHY-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.110726557
  • Average Mass: 345.787
DBSALT000087
Categories
UNII01K63SUP8D
CAS number54910-89-3
WeightAverage: 309.3261
Monoisotopic: 309.134048818
Chemical FormulaC17H18F3NO
InChI KeyRTHCYVBBDHJXIQ-UHFFFAOYSA-N
InChI
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
IUPAC Name
methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
SMILES
CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Pharmacology
IndicationLabeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon.
Structured Indications
PharmacodynamicsFluoxetine, an antidepressant agent belonging to the selective serotonin reuptake inhibitors (SSRIs), is used to treat depression, bulimia nervosa, premenstrual dysphoric disorder, panic disorder and post-traumatic stress. According to the amines hypothesis, a functional decrease in the activity of amines, such as serotonin and norepinephrine, would result in depression; a functional increase of the activity of these amines would result in mood elevation. Fluoxetine's effects are thought to be associated with the inhibition of 5HT receptor, which leads to an increase of serotonin level. Antagonism of muscarinic, histaminergic, and α1–adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.
Mechanism of actionMetabolized to norfluoxetine, fluoxetine is a selective serotonin-reuptake inhibitor (SSRI), it blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Related Articles
AbsorptionWell absorbed from the GI tract following oral administration. Oral bioavailability is estimated to be at least 60-80%. Peak plasma concentrations occur within 6-8 hours following a single oral administration of a 40 mg dose. The oral solution and delayed-release capsule are bioequivalent. Food does not affect the systemic bioavailability of fluoxetine but it delays the absorption by 1-2 hours (not clinically significant). Prozac Weekly capsules, a delayed–release formulation, contain enteric–coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. The enteric coating delays the onset of absorption of fluoxetine 1 to 2 hours relative to the immediate–release formulations.
Volume of distribution
  • 20-45 L/kg
Protein binding94.5% bound to human serum proteins, including albumin and alpha-1-glycoprotein.
Metabolism

Limited data from animal studies suggest that fluoxetine may undergo first-pass metabolism may occur via the liver and/or lungs. Fluoxetine appears to be extensively metabolized, likely in the liver, to norfluoxetine and other metabolites. Norfluoxetine, the principal active metabolite, is formed via N-demethylation of fluoxetine. Norfluoxetine appears to be comparable pharmacologic potency as fluoxetine. Fluoxetine and norfluoxetine both undergo phase II glucuronidation reactions in the liver. It is also thought that fluoxetine and norfluoxetine undergo O-dealkylation to form p-trifluoromethylphenol, which is then subsequently metabolized to hippuric acid.

SubstrateEnzymesProduct
Fluoxetine
NorfluoxetineDetails
Fluoxetine
para-TrifluoromethylphenolDetails
Fluoxetine
Hippuric acidDetails
Fluoxetine
Fluoxetine glucuronideDetails
Norfluoxetine
Norfluoxetine glucuronideDetails
Norfluoxetine
Not Available
Norfluoxetine alcoholDetails
Norfluoxetine alcohol
Not Available
Norfluoxetine acidDetails
Route of eliminationThe primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney. The S-enantiomer is eliminated more slowly and is the predominant enantiomer present at steady state.
Half life1-3 days [acute administration]; 4-6 days [chronic administration]; 4-16 days [norfluoxetine, acute and chronic administration].
ClearanceNot Available
ToxicitySymptoms of overdose include agitation, restlessness, hypomania, and other signs of CNS excitation. LD50=284mg/kg (orally in mice). The most frequent side effects include: nervous system effects such as anxiety, nervousness, insomnia, drowsiness, fatigue or asthenia, tremor, and dizziness or lightheadedness; GI effects such as anorexia, nausea, and diarrhea; vasodilation; dry mouth; abnormal vision; decreased libido; abnormal ejaculation; rash; and sweating. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Fluoxetine Action PathwayDrug actionSMP00426
Fluoxetine Metabolism PathwayDrug metabolismSMP00646
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Fluoxetine.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Fluoxetine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Fluoxetine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Fluoxetine.Experimental
AbirateroneThe serum concentration of Fluoxetine can be increased when it is combined with Abiraterone.Approved
AcarboseFluoxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fluoxetine.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Fluoxetine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Fluoxetine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Fluoxetine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Fluoxetine.Approved
Acetylsalicylic acidFluoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Fluoxetine.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Fluoxetine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluoxetine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluoxetine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Fluoxetine.Approved
AlbiglutideFluoxetine may increase the hypoglycemic activities of Albiglutide.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fluoxetine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluoxetine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Fluoxetine.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Fluoxetine.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fluoxetine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Fluoxetine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Fluoxetine.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluoxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Fluoxetine.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Fluoxetine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fluoxetine.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Fluoxetine.Approved, Withdrawn
AmiodaroneFluoxetine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Fluoxetine.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Fluoxetine.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Fluoxetine.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Fluoxetine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Fluoxetine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Fluoxetine.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Fluoxetine.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Fluoxetine.Approved
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Fluoxetine.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fluoxetine.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
AprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Fluoxetine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Fluoxetine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Fluoxetine.Approved
Arsenic trioxideFluoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherFluoxetine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Fluoxetine.Approved
AsenapineFluoxetine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Fluoxetine.Approved, Withdrawn
AtazanavirThe metabolism of Fluoxetine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fluoxetine.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Fluoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fluoxetine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Azaperone.Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Fluoxetine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Fluoxetine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Fluoxetine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Fluoxetine.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Fluoxetine.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Fluoxetine.Experimental
BendroflumethiazideFluoxetine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Fluoxetine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Fluoxetine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluoxetine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Fluoxetine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Fluoxetine.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Fluoxetine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Fluoxetine.Approved
BexaroteneThe serum concentration of Fluoxetine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBezitramide may increase the serotonergic activities of Fluoxetine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Fluoxetine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluoxetine.Investigational
BoceprevirThe metabolism of Fluoxetine can be decreased when combined with Boceprevir.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Fluoxetine.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
BosentanThe serum concentration of Fluoxetine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluoxetine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluoxetine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Fluoxetine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Fluoxetine.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Fluoxetine.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Fluoxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Fluoxetine.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Fluoxetine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Fluoxetine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Fluoxetine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Fluoxetine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Fluoxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Fluoxetine.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Fluoxetine.Approved
BuspironeBuspirone may increase the serotonergic activities of Fluoxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluoxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Fluoxetine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Fluoxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Fluoxetine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Fluoxetine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Fluoxetine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fluoxetine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluoxetine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Fluoxetine.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fluoxetine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Fluoxetine.Approved
CapecitabineThe metabolism of Fluoxetine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Fluoxetine.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Fluoxetine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Fluoxetine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Fluoxetine.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fluoxetine.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Fluoxetine.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Fluoxetine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Fluoxetine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Fluoxetine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Fluoxetine.Approved, Investigational
CelecoxibFluoxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Fluoxetine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Fluoxetine.Approved, Vet Approved
CeritinibThe serum concentration of Fluoxetine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluoxetine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Fluoxetine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Fluoxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Fluoxetine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Fluoxetine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Fluoxetine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Fluoxetine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluoxetine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
ChlorothiazideFluoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Fluoxetine.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Fluoxetine.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneFluoxetine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Fluoxetine.Approved
CholecalciferolThe metabolism of Fluoxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Fluoxetine.Approved
CimetidineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Fluoxetine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluoxetine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Fluoxetine.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
CisaprideFluoxetine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fluoxetine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Fluoxetine.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Fluoxetine.Approved
ClemastineThe metabolism of Fluoxetine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Fluoxetine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Fluoxetine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Fluoxetine.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Fluoxetine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fluoxetine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Fluoxetine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Fluoxetine.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Fluoxetine resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Fluoxetine.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Fluoxetine.Approved, Illicit
ClotrimazoleThe metabolism of Fluoxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fluoxetine.Approved
CobicistatThe serum concentration of Fluoxetine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fluoxetine.Approved
CocaineThe metabolism of Fluoxetine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluoxetine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluoxetine.Approved
ConivaptanThe serum concentration of Fluoxetine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fluoxetine.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Fluoxetine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Fluoxetine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Fluoxetine.Approved, Investigational
CyclosporineThe metabolism of Fluoxetine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Fluoxetine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluoxetine.Approved
DabrafenibThe serum concentration of Fluoxetine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fluoxetine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Fluoxetine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Fluoxetine.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Fluoxetine.Approved, Investigational
DarunavirThe serum concentration of Fluoxetine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Fluoxetine.Approved
DasatinibThe serum concentration of Fluoxetine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fluoxetine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Fluoxetine.Approved
DeferasiroxThe serum concentration of Fluoxetine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Fluoxetine.Approved
DelavirdineThe metabolism of Fluoxetine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Fluoxetine.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Fluoxetine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Fluoxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Fluoxetine.Vet Approved
DexamethasoneThe serum concentration of Fluoxetine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Fluoxetine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Fluoxetine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Fluoxetine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Fluoxetine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Fluoxetine.Approved, Illicit
DextromethorphanFluoxetine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Fluoxetine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Fluoxetine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fluoxetine.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Fluoxetine.Approved, Vet Approved
DicoumarolFluoxetine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluoxetine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Fluoxetine.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fluoxetine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fluoxetine.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Fluoxetine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluoxetine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Fluoxetine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fluoxetine.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Fluoxetine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Fluoxetine.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Fluoxetine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Fluoxetine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluoxetine.Approved
DisopyramideDisopyramide may increase the QTc-prolonging activities of Fluoxetine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fluoxetine.Approved, Investigational
DofetilideDofetilide may increase the QTc-prolonging activities of Fluoxetine.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Fluoxetine.Approved
DomperidoneFluoxetine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Fluoxetine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Fluoxetine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Fluoxetine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Fluoxetine.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Fluoxetine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluoxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Fluoxetine.Approved, Investigational
DoxycyclineThe metabolism of Fluoxetine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Fluoxetine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Fluoxetine.Investigational
DronabinolThe metabolism of Dronabinol can be decreased when combined with Fluoxetine.Approved, Illicit
DronedaroneFluoxetine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Fluoxetine.Experimental, Illicit
DulaglutideFluoxetine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Fluoxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Fluoxetine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Fluoxetine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluoxetine.Approved
EfavirenzThe serum concentration of Fluoxetine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Fluoxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Fluoxetine.Approved
EmpagliflozinFluoxetine may increase the hypoglycemic activities of Empagliflozin.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Fluoxetine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Fluoxetine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluoxetine.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Fluoxetine.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Fluoxetine.Approved, Investigational
EnzalutamideThe serum concentration of Fluoxetine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Fluoxetine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Fluoxetine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
EscitalopramFluoxetine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Fluoxetine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Esmirtazapine.Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Fluoxetine.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Fluoxetine.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Fluoxetine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fluoxetine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Fluoxetine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluoxetine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Fluoxetine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluoxetine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluoxetine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Fluoxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Fluoxetine.Approved
Ethyl biscoumacetateFluoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Fluoxetine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluoxetine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Fluoxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Fluoxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Fluoxetine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Fluoxetine.Approved
EtodolacFluoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.Approved
EtoperidoneFluoxetine may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fluoxetine.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Fluoxetine.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Fluoxetine.Illicit, Vet Approved
EtravirineThe serum concentration of Fluoxetine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluoxetine.Approved
ExenatideFluoxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fluoxetine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Fluoxetine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Fluoxetine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Fluoxetine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineFluoxetine may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluoxetine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fluoxetine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fluoxetine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Fluoxetine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Fluoxetine.Approved
FloxuridineThe metabolism of Fluoxetine can be decreased when combined with Floxuridine.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Fluoxetine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluoxetine.Approved, Illicit
FluindioneFluoxetine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Fluoxetine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Fluoxetine.Approved, Illicit
FluorouracilThe metabolism of Fluoxetine can be decreased when combined with Fluorouracil.Approved
FlupentixolFluoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Fluoxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Fluoxetine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Fluoxetine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluoxetine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Fluoxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Fluoxetine.Approved
FluvoxamineThe metabolism of Fluoxetine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
FosamprenavirThe metabolism of Fluoxetine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Fluoxetine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Fluoxetine.Approved
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Fluoxetine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Fluoxetine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Fluoxetine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Fluoxetine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Fluoxetine.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Fluoxetine.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Fluoxetine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Fluoxetine.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Fluoxetine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fluoxetine.Approved
GemfibrozilThe metabolism of Fluoxetine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Fluoxetine.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Fluoxetine.Approved
GlimepirideFluoxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideFluoxetine may increase the hypoglycemic activities of Glipizide.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Fluoxetine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Fluoxetine.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Fluoxetine.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Fluoxetine.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fluoxetine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Fluoxetine.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Fluoxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Fluoxetine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Fluoxetine.Approved
HaloperidolFluoxetine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Fluoxetine.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Fluoxetine.Approved, Illicit
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Fluoxetine.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Fluoxetine.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Fluoxetine.Approved
HydrochlorothiazideFluoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
HydroflumethiazideFluoxetine may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Fluoxetine.Approved, Illicit
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Fluoxetine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Fluoxetine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fluoxetine.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Fluoxetine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Fluoxetine.Approved
IdelalisibThe serum concentration of Fluoxetine can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Fluoxetine.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Fluoxetine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Fluoxetine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Fluoxetine.Approved
IndalpineFluoxetine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Fluoxetine.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Fluoxetine.Withdrawn
IndinavirThe metabolism of Fluoxetine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fluoxetine.Approved, Investigational
Insulin AspartFluoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirFluoxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineFluoxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineFluoxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanFluoxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproFluoxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Fluoxetine.Approved
Ioflupane I-123Fluoxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Fluoxetine.Approved
IproclozideIproclozide may increase the serotonergic activities of Fluoxetine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Fluoxetine.Withdrawn
IrbesartanThe metabolism of Fluoxetine can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fluoxetine.Approved, Investigational
IsavuconazoniumThe metabolism of Fluoxetine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Fluoxetine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
IsoniazidThe metabolism of Fluoxetine can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Fluoxetine.Approved
ItraconazoleThe metabolism of Fluoxetine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Fluoxetine.Approved
IvacaftorThe serum concentration of Fluoxetine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Fluoxetine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluoxetine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Fluoxetine.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Fluoxetine.Approved
KetoconazoleThe metabolism of Fluoxetine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Fluoxetine.Approved, Nutraceutical
LabetalolThe metabolism of Labetalol can be decreased when combined with Fluoxetine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fluoxetine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fluoxetine.Approved, Investigational
LanreotideFluoxetine may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fluoxetine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluoxetine.Approved
LeflunomideThe metabolism of Fluoxetine can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fluoxetine.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Fluoxetine.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fluoxetine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Fluoxetine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fluoxetine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Fluoxetine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Fluoxetine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Fluoxetine.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Fluoxetine.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Fluoxetine.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Fluoxetine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluoxetine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Fluoxetine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fluoxetine.Approved
LinezolidLinezolid may increase the serotonergic activities of Fluoxetine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluoxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Fluoxetine.Approved
LiraglutideFluoxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Fluoxetine.Approved
LithiumLithium may increase the serotonergic activities of Fluoxetine.Approved
LofentanilLofentanil may increase the serotonergic activities of Fluoxetine.Illicit
LomustineThe metabolism of Lomustine can be decreased when combined with Fluoxetine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Fluoxetine.Approved
LopinavirFluoxetine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Fluoxetine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluoxetine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Fluoxetine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Fluoxetine.Approved
LovastatinThe metabolism of Fluoxetine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Loxapine.Approved
Lu AA21004Fluoxetine may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Fluoxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Fluoxetine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineFluoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibFluoxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Lurasidone.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Fluoxetine.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Fluoxetine.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Fluoxetine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Fluoxetine.Approved
MebanazineMebanazine may increase the serotonergic activities of Fluoxetine.Withdrawn
MecaserminFluoxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Fluoxetine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Fluoxetine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Fluoxetine.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Fluoxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Melperone.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Fluoxetine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluoxetine.Approved, Vet Approved
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Fluoxetine.Approved, Illicit
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Fluoxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Fluoxetine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.Approved
MetforminFluoxetine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Fluoxetine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Fluoxetine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Fluoxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluoxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Fluoxetine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluoxetine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fluoxetine.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Fluoxetine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Fluoxetine.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Fluoxetine.Approved
MethyclothiazideFluoxetine may increase the hyponatremic activities of Methyclothiazide.Approved
Methylene blueFluoxetine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Fluoxetine.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Fluoxetine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Fluoxetine.Approved, Illicit, Withdrawn
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Fluoxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.Approved, Investigational
MetolazoneFluoxetine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Fluoxetine.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluoxetine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Fluoxetine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Fluoxetine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fluoxetine.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
MiglitolFluoxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Fluoxetine.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Fluoxetine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Fluoxetine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fluoxetine.Approved, Investigational
MoclobemideMoclobemide may increase the serotonergic activities of Fluoxetine.Approved
ModafinilThe serum concentration of Fluoxetine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Fluoxetine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Fluoxetine.Approved, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Fluoxetine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluoxetine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Fluoxetine.Approved, Investigational
NabumetoneFluoxetine may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Fluoxetine.Approved
NafcillinThe serum concentration of Fluoxetine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Fluoxetine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluoxetine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Fluoxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.Approved, Investigational
NefazodoneThe metabolism of Fluoxetine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Fluoxetine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Fluoxetine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Fluoxetine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Fluoxetine.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Fluoxetine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Fluoxetine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Fluoxetine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nifedipine.Approved
NilotinibFluoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Fluoxetine.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Fluoxetine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluoxetine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Fluoxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Fluoxetine.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Fluoxetine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fluoxetine.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved
NormethadoneNormethadone may increase the serotonergic activities of Fluoxetine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Fluoxetine.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
OlaparibThe metabolism of Fluoxetine can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Fluoxetine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluoxetine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fluoxetine.Approved
OmeprazoleThe metabolism of Fluoxetine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Fluoxetine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Opipramol.Investigational
OpiumOpium may increase the serotonergic activities of Fluoxetine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Fluoxetine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Fluoxetine can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Fluoxetine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluoxetine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Fluoxetine.Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Fluoxetine.Approved
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Fluoxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluoxetine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Fluoxetine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Fluoxetine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PalbociclibThe serum concentration of Fluoxetine can be increased when it is combined with Palbociclib.Approved
PaliperidoneFluoxetine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Fluoxetine.Approved, Investigational
PanobinostatThe serum concentration of Fluoxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Fluoxetine can be decreased when combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Fluoxetine.Approved
ParecoxibFluoxetine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Fluoxetine.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Fluoxetine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.Approved
Peginterferon alfa-2bThe serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Fluoxetine.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Fluoxetine.Approved
PentazocinePentazocine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
PentobarbitalThe metabolism of Fluoxetine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Fluoxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Fluoxetine.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Fluoxetine.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Fluoxetine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Fluoxetine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Fluoxetine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Fluoxetine.Withdrawn
PhenelzinePhenelzine may increase the serotonergic activities of Fluoxetine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Fluoxetine.Approved, Withdrawn
PhenindioneFluoxetine may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PhenobarbitalThe metabolism of Fluoxetine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Fluoxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PhenprocoumonFluoxetine may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PimozideFluoxetine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Fluoxetine.Approved
PioglitazoneFluoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Fluoxetine.Approved
PiritramidePiritramide may increase the serotonergic activities of Fluoxetine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Fluoxetine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluoxetine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Fluoxetine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Fluoxetine.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Fluoxetine.Approved
PolythiazideFluoxetine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fluoxetine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Fluoxetine.Approved
PosaconazoleThe metabolism of Fluoxetine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Fluoxetine.Approved
PramlintideFluoxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Fluoxetine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Fluoxetine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluoxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Fluoxetine.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fluoxetine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluoxetine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Fluoxetine.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Fluoxetine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Fluoxetine.Approved
PrimidoneThe metabolism of Fluoxetine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideFluoxetine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Fluoxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Fluoxetine.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Fluoxetine.Approved
PromazinePromazine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Fluoxetine.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Fluoxetine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Fluoxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Fluoxetine.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Fluoxetine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Fluoxetine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluoxetine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Fluoxetine.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Fluoxetine.Approved
PyrimethamineThe metabolism of Fluoxetine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Fluoxetine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineFluoxetine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneFluoxetine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineFluoxetine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Fluoxetine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Fluoxetine.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Raclopride.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Fluoxetine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Fluoxetine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluoxetine.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Fluoxetine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Fluoxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Fluoxetine.Approved, Withdrawn
RepaglinideFluoxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Fluoxetine.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Fluoxetine.Approved
RifabutinThe metabolism of Fluoxetine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Fluoxetine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Fluoxetine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluoxetine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Fluoxetine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Fluoxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Fluoxetine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fluoxetine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Rizatriptan.Approved
RofecoxibFluoxetine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Fluoxetine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Fluoxetine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Fluoxetine.Vet Approved
RopiniroleThe metabolism of Fluoxetine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Fluoxetine.Approved
RosiglitazoneFluoxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Fluoxetine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Fluoxetine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Fluoxetine.Experimental
SafrazineSafrazine may increase the serotonergic activities of Fluoxetine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Fluoxetine.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fluoxetine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Fluoxetine.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
SaxagliptinFluoxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Fluoxetine.Approved
SecobarbitalThe metabolism of Fluoxetine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Fluoxetine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fluoxetine.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Fluoxetine.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Fluoxetine.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Fluoxetine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Fluoxetine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluoxetine.Approved
SiltuximabThe serum concentration of Fluoxetine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Fluoxetine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Fluoxetine.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Fluoxetine.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Fluoxetine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fluoxetine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Fluoxetine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
SotalolFluoxetine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fluoxetine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Fluoxetine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fluoxetine.Experimental
St. John's WortThe serum concentration of Fluoxetine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Fluoxetine can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Fluoxetine.Approved, Investigational
SulfadiazineThe metabolism of Fluoxetine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Fluoxetine.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Fluoxetine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Fluoxetine.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Fluoxetine.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluoxetine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Fluoxetine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Fluoxetine.Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Fluoxetine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Fluoxetine.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluoxetine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fluoxetine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Fluoxetine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Fluoxetine.Investigational, Withdrawn
TelaprevirThe metabolism of Fluoxetine can be decreased when combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Fluoxetine.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Fluoxetine.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Fluoxetine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fluoxetine.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Fluoxetine.Approved
TenofovirThe metabolism of Fluoxetine can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Fluoxetine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Fluoxetine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Fluoxetine.Withdrawn
TeriflunomideThe serum concentration of Fluoxetine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Fluoxetine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Fluoxetine.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Fluoxetine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Fluoxetine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Fluoxetine.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Fluoxetine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Fluoxetine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluoxetine.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Fluoxetine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Fluoxetine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Thioproperazine.Approved
ThioridazineFluoxetine may increase the QTc-prolonging activities of Thioridazine.Approved
ThiotepaThe metabolism of Fluoxetine can be decreased when combined with Thiotepa.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Fluoxetine.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluoxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Fluoxetine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tianeptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fluoxetine.Approved
TiclopidineThe metabolism of Fluoxetine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Fluoxetine.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Fluoxetine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Fluoxetine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Fluoxetine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluoxetine.Approved
TocilizumabThe serum concentration of Fluoxetine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Fluoxetine.Approved, Investigational
TolazamideFluoxetine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Fluoxetine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fluoxetine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Fluoxetine.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluoxetine.Approved
TopiramateThe metabolism of Fluoxetine can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluoxetine.Approved, Investigational
ToremifeneFluoxetine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Fluoxetine.Approved, Investigational
TramadolFluoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Fluoxetine.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Fluoxetine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fluoxetine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Fluoxetine.Approved
TrichlormethiazideFluoxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Fluoxetine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluoxetine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Fluoxetine.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Fluoxetine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Fluoxetine.Withdrawn
TropisetronTropisetron may increase the serotonergic activities of Fluoxetine.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Fluoxetine.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fluoxetine.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Fluoxetine.Approved
ValdecoxibFluoxetine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Fluoxetine.Approved, Investigational
ValsartanThe metabolism of Fluoxetine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibFluoxetine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Fluoxetine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fluoxetine.Approved
VemurafenibThe serum concentration of Fluoxetine can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Fluoxetine.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Fluoxetine.Approved
VerapamilThe metabolism of Fluoxetine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Fluoxetine.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Fluoxetine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Fluoxetine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Fluoxetine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fluoxetine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Fluoxetine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fluoxetine.Approved
VoriconazoleThe metabolism of Fluoxetine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Fluoxetine.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Fluoxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Fluoxetine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Fluoxetine.Approved, Vet Approved
ZafirlukastThe metabolism of Fluoxetine can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Fluoxetine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluoxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Fluoxetine.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Fluoxetine.Approved
ZimelidineFluoxetine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneFluoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Fluoxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluoxetine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Fluoxetine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluoxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Fluoxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Zotepine.Approved
ZuclopenthixolFluoxetine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation and nausea.
References
Synthesis Reference

Eduard Schwartz, Joseph Kaspi, Zinovi Itov, Gidon Pilarski, “Production of fluoxetine and new intermediates.” U.S. Patent US5225585, issued October, 1990.

US5225585
General References
  1. Wong DT, Bymaster FP, Engleman EA: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57(5):411-41. [PubMed:7623609 ]
  2. Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB: A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974 Aug 1;15(3):471-9. [PubMed:4549929 ]
  3. Carlsson A, Wong DT: Correction: a note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 1997;61(12):1203. [PubMed:9315511 ]
  4. Gerber PE, Lynd LD: Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998 Jun;32(6):692-8. [PubMed:9640489 ]
  5. Caley CF: Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997 Dec;31(12):1481-9. [PubMed:9416386 ]
External Links
ATC CodesN06CA03N06AB03
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (194 KB)
MSDSDownload (76.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.983
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5899
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.5459
Renal organic cation transporterInhibitor0.5633
CYP450 2C9 substrateNon-substrate0.7475
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5754
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7149
Ames testNon AMES toxic0.7105
CarcinogenicityNon-carcinogens0.8089
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity2.6048 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6058
hERG inhibition (predictor II)Inhibitor0.8467
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Dr reddys laboratories ltd
  • Eli lilly and co
  • Mutual pharmacal co
  • Watson laboratories inc
  • Alembic ltd
  • Alphapharm party ltd
  • Aurobindo pharma ltd
  • Beijing double crane pharmaceutical co ltd
  • Carlsbad technology inc
  • Dr reddys laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Landela pharmaceutical
  • Mallinckrodt inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Lilly research laboratories div eli lilly and co
  • Actavis mid atlantic llc
  • Aurobindo pharma usa inc
  • Hi tech pharmacal co inc
  • Lannett holdings inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Warner chilcott inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
CapsuleOral40 mg/1
LiquidOral20 mg/5mL
SolutionOral20 mg/5mL
Tablet, film coatedOral60 mg/1
CapsuleOral20 mg/1
Capsule, delayed release pelletsOral90 mg/1
TabletOral10 mg/1
TabletOral20 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral20 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
CapsuleOral40 mg
Kit
CapsuleOral
SolutionOral20 mg
CapsuleOral20 mg
CapsuleOral10 mg
LiquidOral20 mg
Capsule, delayed releaseOral90 mg/1
Prices
Unit descriptionCostUnit
PROzac 20 mg/5ml Solution 120ml Bottle266.51USD bottle
PROzac Weekly 1 Package = 4 capsule (90 mg) Disp Pack140.77USD disp
Sarafem 7 10 mg tablet Box61.08USD box
Sarafem 7 20 mg tablet Each Box Contains 7 tablet59.55USD box
Prozac weekly 90 mg capsule34.5USD capsule
PROzac 40 mg capsule13.89USD capsule
Fluoxetine hcl powder8.32USD g
Sarafem 10 mg tablet7.91USD tablet
Sarafem 15 mg tablet7.91USD tablet
Sarafem 20 mg tablet7.91USD tablet
PROzac 20 mg capsule6.95USD capsule
PROzac 10 mg capsule6.77USD capsule
FLUoxetine HCl 40 mg capsule5.54USD capsule
PROzac 10 mg tablet4.31USD tablet
Fluoxetine hcl 20 mg tablet4.26USD tablet
Rapiflux 20 mg tablet3.11USD tablet
FLUoxetine HCl 20 mg capsule2.77USD capsule
Fluoxetine hcl 10 mg tablet2.72USD tablet
FLUoxetine HCl 10 mg capsule2.7USD capsule
Fxt 40 40 mg Capsule2.3USD capsule
Prozac 10 mg Capsule2.02USD capsule
Prozac 20 mg Capsule2.02USD capsule
Apo-Fluoxetine 10 mg Capsule1.13USD capsule
Co Fluoxetine 10 mg Capsule1.13USD capsule
Mylan-Fluoxetine 10 mg Capsule1.13USD capsule
Novo-Fluoxetine 10 mg Capsule1.13USD capsule
Nu-Fluoxetine 10 mg Capsule1.13USD capsule
Phl-Fluoxetine 10 mg Capsule1.13USD capsule
Pms-Fluoxetine 10 mg Capsule1.13USD capsule
Ratio-Fluoxetine Hydrochloride 10 mg Capsule1.13USD capsule
Sandoz Fluoxetine 10 mg Capsule1.13USD capsule
Apo-Fluoxetine 20 mg Capsule1.06USD capsule
Co Fluoxetine 20 mg Capsule1.06USD capsule
Mylan-Fluoxetine 20 mg Capsule1.06USD capsule
Novo-Fluoxetine 20 mg Capsule1.06USD capsule
Nu-Fluoxetine 20 mg Capsule1.06USD capsule
Phl-Fluoxetine 20 mg Capsule1.06USD capsule
Pms-Fluoxetine 20 mg Capsule1.06USD capsule
Ratio-Fluoxetine Hydrochloride 20 mg Capsule1.06USD capsule
Sandoz Fluoxetine 20 mg Capsule1.06USD capsule
FLUoxetine HCl 20 mg/5ml Solution1.03USD ml
Apo-Fluoxetine 4 mg/ml Liquid0.61USD liquid
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5910319 Yes1997-11-292017-11-29Us
US5945416 No1997-03-242017-03-24Us
US5985322 Yes1997-11-292017-11-29Us
US6960577 No1997-11-012017-11-01Us
USRE39030 No1997-05-292017-05-29Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point179-182 °CNot Available
water solubility50 mg/mL at 25 °CNot Available
logP4.05ADLARD,M ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0017 mg/mLALOGPS
logP4.09ALOGPS
logP4.17ChemAxon
logS-5.3ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity80.37 m3·mol-1ChemAxon
Polarizability30.33 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-9200000000-dcf68dbfd090c7fdfe11View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenol ether
  • Aralkylamine
  • Alkyl aryl ether
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Richman A, Heinrichs SC: Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation. Epilepsy Res. 2007 Apr;74(1):19-27. Epub 2007 Jan 9. [PubMed:17215106 ]
  2. Iceta R, Mesonero JE, Alcalde AI: Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells. Life Sci. 2007 Mar 27;80(16):1517-24. Epub 2007 Jan 20. [PubMed:17289086 ]
  3. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951 ]
  4. Sanders AC, Hussain AJ, Hen R, Zhuang X: Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward. Neuropsychopharmacology. 2007 Nov;32(11):2321-9. Epub 2007 Mar 14. [PubMed:17356573 ]
  5. Goren MZ, Kucukibrahimoglu E, Berkman K, Terzioglu B: Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochem Res. 2007 Sep;32(9):1559-65. Epub 2007 May 8. [PubMed:17486443 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  3. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  4. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  5. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  6. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS: (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. [PubMed:10997938 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54